Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Adolfo de la Fuente"'
Autor:
Yu-Hung Wang, Adrián Mosquera Orgueira, Chien-Chin Lin, Chi-Yuan Yao, Min-Yen Lo, Cheng-Hong Tsai, Adolfo de la Fuente Burguera, Hsin-An Hou, Wen-Chien Chou, Hwei-Fang Tien
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract The European Leukemia Net recommendations provide valuable guidance in treatment decisions of patients with acute myeloid leukemia (AML). However, the genetic complexity and heterogeneity of AML are not fully covered, notwithstanding that ge
Externí odkaz:
https://doaj.org/article/6ead356802e74eccaafc335f241b2a39
Autor:
Teresa Bernal, Ainhoa Fernández Moreno, Almudena de LaIglesia, Celina Benavente, Ana García‐Noblejas, Daniel García Belmonte, Rosalía Riaza, Olga Salamero, Maria Angeles Foncillas, Alicia Roldán, Víctor Noriega Concepción, Laura Llorente González, Juan Miguel Bergua Burgués, Soraya Lorente de Uña, Gabriela Rodríguez‐Macías, Adolfo de la Fuente Burguera, Maria José García Pérez, Jose Luis López‐Lorenzo, Pilar Martínez, Concepción Aláez, Marta Callejas, Carmen Martínez‐Chamorro, José Rifón Roca, Lourdes Amador Barciela, Armando V. Mena Durán, Karoll Gómez Correcha, Esperanza Lavilla Rubira, María Luz Amigo, Ferran Vall‐llovera, Ana Garrido, María García‐Fortes, Dunia de Miguel Llorente, Anastasia Aules Leonardo, Carlos Cervero, Rosa Coll Jordá, Manuel M. Pérez‐Encinas, Marta Polo Zarzuela, Angela Figuera, Guillermo Rad, David Martínez‐Cuadrón, Pau Montesinos
Publikováno v:
Cancer Medicine, Vol 12, Iss 14, Pp 14892-14901 (2023)
Abstract Background CPX‐351 is approved for the treatment of therapy related acute myeloid leukemia (t‐AML) and AML with myelodysplastic related changes (MRC‐AML). The benefits of this treatment over standard chemotherapy has not been addressed
Externí odkaz:
https://doaj.org/article/9c1db4405e274742a000602740ddeff0
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, José Ángel Díaz Arias, Beatriz Antelo Rodríguez, Mónica López Riñón, Claudio Cerchione, Adolfo de la Fuente Burguera, Marta Sonia González Pérez, Giovanni Martinelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/5b644d52caf6407c83da3785ab40f5bd
Autor:
Mariana Bastos-Oreiro, Antonio Gutierrez, Almudena Cabero, Javier López, Paola Villafuerte, Ana Jiménez-Ubieto, Raquel de Oña, Adolfo De la Fuente, Belén Navarro, Javier Peñalver, Pilar Martínez, Carmen Alonso, María Infante, Raúl Córdoba, Blanca Perez-Montero, Jaime Pérez de Oteyza, Sonia González de Villambrosio, Paula Fernández-Caldas, Raquel del Campo, Daniel García Belmonte, Javier Diaz-Gálvez, Antonio Salar, Juan-Manuel Sancho
Publikováno v:
Cancers, Vol 16, Iss 7, p 1285 (2024)
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and R-bendamustine (R-B) are the most common frontline treatment strategies for advanced-stage follicular lymphoma (FL). After R-CHOP induction therapy, using rituximab fo
Externí odkaz:
https://doaj.org/article/dd29271880a84c71b957bac27df479a7
Autor:
Mar Tormo, Marina Diaz-Beya, Paola Beneit, Ainhoa Fernández Moreno, Montserrat Arnan, Ana Garrido Diaz, Susana Vives, Maria García Fortes, Antonia Sampol, Jorge Labrador, Antonio Garcia-Guiñon, Carmen Botella, Juan Miguel Bergua Burgues, Mayte Olave, Maria Luz Amigo, Xavier Ortín, Ferrand Ferran Vall-Llovera, Maria Pereiro, Josefina Serrano, Maria Jose Sayas Lloris, Almudena De Laiglesia Lorenzo, Juan Jose Bargay Lleonart, Maria Luisa Calabuig Muñoz, Adolfo De La Fuente
Publikováno v:
HemaSphere, Vol 7, p e4025574 (2023)
Externí odkaz:
https://doaj.org/article/94b6da21d4b64549a1fd78634dbb7199
Autor:
Emilie Bérard, Christoph Röllig, Sarah Bertoli, Arnaud Pigneux, Suzanne Tavitian, Michael Kramer, Hubert Serve, Martin Bornhäuser, Uwe Platzbecker, Carsten Müller-Tidow, Claudia D. Baldus, David Martínez-Cuadrón, Josefina Serrano, Pilar Martínez-Sánchez, Eduardo Rodríguez Arbolí, Cristina Gil, Juan Bergua, Teresa Bernal, Adolfo de la Fuente Burguera, Eric Delabesse, Audrey Bidet, Pierre-Yves Dumas, Pau Montesinos, Christian Récher
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 7, Pp 1-8 (2022)
Abstract In a context of therapeutic revolution in older adults with AML, it is becoming increasingly important to select patients for the various treatment options by taking account of short-term efficacy and toxicity as well as long-term survival.
Externí odkaz:
https://doaj.org/article/a79de68b14424fe89380e50d0b454990
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, José Ángel Díaz Arias, Beatriz Antelo Rodríguez, Mónica López Riñón, Claudio Cerchione, Adolfo de la Fuente Burguera, Marta Sonia González Pérez, Giovanni Martinelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Risk stratification in acute myeloid leukemia (AML) has been extensively improved thanks to the incorporation of recurrent cytogenomic alterations into risk stratification guidelines. However, mortality rates among fit patients assigned to low or int
Externí odkaz:
https://doaj.org/article/5aede6c8b7c54ba38df284fa7e1db4fd
Autor:
Joaquín Martínez-López, Javier De la Cruz, Rodrigo Gil-Manso, Adrián Alegre, Javier Ortiz, Pilar Llamas, Yolanda Martínez, José-Ángel Hernández-Rivas, Isabel González-Gascón, Celina Benavente, Pablo Estival Monteliu, Víctor Jiménez-Yuste, Miguel Canales, Mariana Bastos, Mi Kwon, Susana Valenciano, Marta Callejas-Charavia, Javier López-Jiménez, Pilar Herrera, Rafael Duarte, Lucía Núñez Martín-Buitrago, Pedro Sanchez Godoy, Cristina Jacome Yerovi, Pilar Martínez-Barranco, María García Roa, Cristian Escolano Escobar, Arturo Matilla, Belén Rosado Sierra, María Concepción Aláez-Usón, Keina Quiroz-Cervantes, Carmen Martínez-Chamorro, Jaime Pérez-Oteyza, Rafael Martos-Martinez, Regina Herráez, Clara González-Santillana, Juan Francisco Del Campo, Arancha Alonso, Adolfo de la Fuente, Adriana Pascual, Rosalía Bustelos-Rodriguez, Ana Sebrango, Elena Ruiz, Eriel Alexis Marcheco-Pupo, Carlos Grande, Ángel Cedillo, Carlos Lumbreras, Andrés Arroyo Barea, José Manuel Casas-Rojo, Maria Calbacho, José Luis Diez-Martín, Julio García-Suárez
Publikováno v:
Cancers, Vol 15, Iss 5, p 1497 (2023)
Mortality rates for COVID-19 have declined over time in the general population, but data in patients with hematologic malignancies are contradictory. We identified independent prognostic factors for COVID-19 severity and survival in unvaccinated pati
Externí odkaz:
https://doaj.org/article/750d10fa2c364b1781febffdc53f62fe
Autor:
Julio García-Suárez, Javier de la Cruz, Ángel Cedillo, Pilar Llamas, Rafael Duarte, Víctor Jiménez-Yuste, José Ángel Hernández-Rivas, Rodrigo Gil-Manso, Mi Kwon, Pedro Sánchez-Godoy, Pilar Martínez-Barranco, Blanca Colás-Lahuerta, Pilar Herrera, Laurentino Benito-Parra, Adrián Alegre, Alberto Velasco, Arturo Matilla, María Concepción Aláez-Usón, Rafael Martos-Martínez, Carmen Martínez-Chamorro, Keina Susana-Quiroz, Juan Francisco Del Campo, Adolfo de la Fuente, Regina Herráez, Adriana Pascual, Elvira Gómez, Jaime Pérez-Oteyza, Elena Ruiz, Arancha Alonso, José González-Medina, Lucía Núñez Martín-Buitrago, Miguel Canales, Isabel González-Gascón, María Carmen Vicente-Ayuso, Susana Valenciano, María García Roa, Pablo Estival Monteliu, Javier López-Jiménez, Cristián Escolano Escobar, Javier Ortiz-Martín, José Luis Diez-Martin, Joaquín Martinez-Lopez, the Asociación Madrileña de Hematología y Hemoterapia (AMHH)
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-12 (2020)
Abstract Background Patients with cancer have been shown to have a higher risk of clinical severity and mortality compared to non-cancer patients with COVID-19. Patients with hematologic malignancies typically are known to have higher levels of immun
Externí odkaz:
https://doaj.org/article/a3adfa6f2a6e43bc89a85fd388a33caa
Autor:
Alessandro Isidori, Claudio Cerchione, Naval Daver, Courtney DiNardo, Guillermo Garcia-Manero, Marina Konopleva, Elias Jabbour, Farhad Ravandi, Tapan Kadia, Adolfo de la Fuente Burguera, Alessandra Romano, Federica Loscocco, Giuseppe Visani, Giovanni Martinelli, Hagop Kantarjian, Antonio Curti
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
In the past few years, our improved knowledge of acute myeloid leukemia (AML) pathogenesis has led to the accelerated discovery of new drugs and the development of innovative therapeutic approaches. The role of the immune system in AML development, g
Externí odkaz:
https://doaj.org/article/a6e56f3f011e4e9596bb57c9ced75c4c